Kiniksa Pharmaceuticals, Ltd

(NASDAQ:KNSA)

Latest On Kiniksa Pharmaceuticals, Ltd (KNSA):

Date/Time Type Description Signal Details
2023-05-08 12:04 ESTNewsKiniksa Pharmaceuticals, Ltd. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-06 16:45 ESTNewsKiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2023 Earnings Call TranscriptN/A
2023-05-02 23:49 ESTNewsKiniksa jumps 14% after guidance raise for Arcalyst pericarditis therapyN/A
2023-05-02 11:18 ESTNewsKiniksa Pharmaceuticals GAAP EPS of -$0.18, revenue of $48.3MN/A
2023-03-02 03:28 ESTNewsKiniksa Pharmaceuticals, Ltd. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-02-28 21:51 ESTNewsKiniksa Pharmaceuticals GAAP EPS of $0.06, revenue of $61.88MN/A
2023-02-28 21:50 ESTNewsKiniksa Pharmaceuticals, Ltd. (KNSA) Q4 2022 Earnings Call TranscriptN/A
2023-02-19 21:34 ESTNewsKiniksa: Steady Progress With Arcalyst, But Still Pretty UnexcitingN/A
2023-01-20 19:14 ESTNewsKiniksa Pharmaceuticals (KNSA) Presents At 41st Annual Healthcare Conference - SlideshowN/A
2022-12-03 00:38 ESTNewsKiniksa Pharmaceuticals: This Enterprising BioTech Should Be On Your Stock WatchlistN/A
2022-11-02 03:15 ESTNewsKiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call TranscriptN/A
2022-11-01 11:18 ESTNewsKiniksa Pharmaceuticals GAAP EPS of $3.18, revenue of $99.13MN/A
2022-11-01 11:18 ESTNewsKiniksa Pharmaceuticals, Ltd. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-08-07 02:38 ESTNewsKiniksa Pharmaceuticals (KNSA) Investor Presentation - SlideshowN/A
2022-08-05 20:00 ESTNewsKiniksa Pharmaceuticals, Ltd. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-05 20:00 ESTNewsKiniksa Pharmaceuticals, Ltd. (KNSA) CEO Sanj Patel on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 22:22 ESTNewsKiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidanceN/A
2022-08-03 22:21 ESTNewsKiniksa in licensing pact with Roche unit Genentech for fibrosis candidateN/A
2022-05-07 23:59 ESTNewsKiniksa Pharmaceuticals (KNSA) CEO Sanj Patel on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-07 03:52 ESTNewsKiniksa Pharmaceuticals files for $400M mixed shelf offeringN/A
2022-05-03 16:16 ESTNewsKiniksa Pharmaceuticals GAAP EPS of -$0.36 misses by $0.03, revenue of $32.18MN/A
2022-03-10 01:29 ESTNewsUnited Therapeutics slips as first to receive a pig heart transplant diesN/A
2022-02-23 02:14 ESTNewsKiniksa Pharmaceuticals GAAP EPS of -$0.53 misses by $0.13, revenue of $18.7M beats by $1.12MN/A
2022-02-23 02:14 ESTNewsKiniksa Pharmaceuticals, Ltd. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-02-23 02:14 ESTNewsKiniksa Pharmaceuticals (KNSA) CEO Sanj Patel on Q4 2021 Results - Earnings Call TranscriptN/A
2022-01-24 22:30 ESTNewsKiniksa Pharmaceuticals (KNSA) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceN/A
2022-01-11 14:08 ESTNewsUnited Therapeutics, Kiniksa take off on pig-to-human heart transplantN/A
2021-12-28 09:44 ESTNewsKiniksa says late-stage trial for COVID-19 antibody therapy did not meet main goalN/A
2021-11-25 22:45 ESTNewsKiniksa: Latest Earnings Beat Shows Light At The End Of The TunnelN/A
2021-11-02 18:19 ESTNewsKiniksa strong gains continue for a second day following earnings beat, guidanceN/A
2021-11-01 22:03 ESTNewsKiniksa Pharmaceuticals EPS beats by $0.19, beats on revenueN/A
2021-11-01 22:02 ESTNewsKiniksa Pharmaceuticals (KNSA) CEO, Sanj Patel on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-01 22:02 ESTNewsKiniksa Pharmaceuticals, Ltd. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-01 22:01 ESTNewsKiniksa posts a record gain as outlook beats estimatesN/A
2021-11-01 02:34 ESTNewsKiniksa Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-10-07 14:01 ESTNewsKiniksa Pharmaceuticals Ltd (KNSA) Presents at Global Healthcare Virtual Conference - SlideshowN/A
2021-08-13 15:45 ESTNewsKiniksa Pharmaceuticals, Ltd. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-13 15:44 ESTNewsKiniksa: Unexciting, Slow Growth StockN/A
2021-08-04 09:43 ESTNewsKiniksa reports positive data for COVID-19 respiratory syndrome candidateN/A
2021-08-03 13:40 ESTNewsKiniksa Pharmaceuticals EPS misses by $0.66, beats on revenueN/A
2021-08-03 13:39 ESTNewsKiniksa Pharmaceuticals' (KNSA) CEO Sanj Patel on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-21 13:29 ESTNewsKiniksa outlines development path for mavrilimumab after FDA feedbackN/A
2021-07-21 13:28 ESTNewsKiniksa issued U.S. patent for treatment of recurrent pericarditisN/A
2021-07-21 13:13 ESTNewsCRISPR, Omeros among “actionable” SMID-cap biopharma for H2 2021 at BofAN/A
2021-05-04 21:59 ESTNewsKiniksa Pharmaceuticals EPS misses by $0.08N/A
2021-05-04 00:57 ESTNewsKiniksa: A Look At MavrilimumabN/A
2021-04-12 21:54 ESTNewsKiniksa posts positive results from mid-stage mavrilimumab COVID-19 trialN/A
2021-03-19 21:11 ESTNewsIdera suffers downgrades after trial setback; Kiniksa target upped on FDA win; and more in today’s analyst callsN/A
2021-03-19 21:11 ESTNewsMP, CLVS, SOS and TNXP among premarket gainersN/A
2021-03-19 21:10 ESTNewsKiniksa price target raised at BofA; says FDA win was widely-expectedN/A

About Kiniksa Pharmaceuticals, Ltd (KNSA):

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

KNSA Quotes by TradingView

See Advanced Chart

General

  • Name Kiniksa Pharmaceuticals, Ltd
  • Symbol KNSA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 168
  • Fiscal Year EndDecember
  • IPO Date2018-05-24
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.kiniksa.com
View More

Valuation

  • Trailing PE 5.09
  • Price/Book (Most Recent Quarter) 4.91
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.95
  • Next Year EPS Estimate -$2.47
  • Next Quarter EPS Estimate -$0.68
  • Return on Assets -33%
  • Return on Equity -60%
  • Earnings Per Share -$3.34
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.48 billion
  • EBITDA -175984000
  • Analyst Target Price $34
  • Book Value Per Share $4.57
View More

Share Statistics

  • Shares Outstanding 31.92 million
  • Shares Float 26.81 million
  • % Held by Insiders 618%
  • % Held by Institutions 87.31%
  • Shares Short 3.87 million
  • Shares Short Prior Month 3.79 million
  • Short Ratio 11.13
  • Short % of Float 14%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • 52 Week High $26.14
  • 52 Week Low $11.51
  • 50 Day Moving Average 21.85
  • 200 Day Moving Average 18.57
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Kiniksa Pharmaceuticals, Ltd (KNSA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Kiniksa Pharmaceuticals, Ltd (KNSA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-23$N/A-$0.79-$0.61-30.04%
2020-09-302020-11-05$N/A-$0.66-$0.59-11.39%
2020-06-302020-07-30$N/A-$0.65-$0.59-11.11%
2020-03-312020-04-28$N/A-$0.48-$0.6222.08%
2019-12-312020-02-26$N/A-$0.58-$0.7623.69%
2019-09-302019-10-28$N/A-$0.49-$0.7029.85%
2019-06-302019-08-12$N/A-$0.68-$0.7610.21%
2019-03-312019-05-02$N/A-$0.73-$0.797.81%
2018-12-312019-03-07$N/A-$0.88-$0.74-18.61%
2018-09-302018-11-01$N/A-$0.51-$0.544.67%
2018-06-302018-08-06$N/A-$0.47-$0.506.88%
2018-03-312018-05-24$N/A-$0.32

Kiniksa Pharmaceuticals, Ltd (KNSA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Kiniksa Pharmaceuticals, Ltd (KNSA) Chart:

Kiniksa Pharmaceuticals, Ltd (KNSA) News:

Below you will find a list of latest news for Kiniksa Pharmaceuticals, Ltd (KNSA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Kiniksa Pharmaceuticals, Ltd (KNSA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-11-1512.50CALL0 092.01TRUE00
2024-11-15150CALL0 094.03TRUE00
2024-11-1517.50CALL0 068.62TRUE00
2024-11-15205.49CALL0 061.99TRUE00
2024-11-1522.50CALL0 065.51TRUE00
2024-11-15252.55CALL0 479.68TRUE00
2024-11-15300CALL0 00FALSE00
2024-11-15350CALL0 00FALSE00
2024-11-1512.50PUT0 00FALSE00
2024-11-15150PUT0 00FALSE00
2024-11-1517.50PUT0 00FALSE00
2024-11-15200PUT0 00FALSE00
2024-11-1522.50PUT0 00FALSE00
2024-11-15250PUT0 00FALSE00
2024-11-15300PUT0 060.81TRUE00
2024-11-15350PUT0 070.81TRUE00
2025-01-172.50CALL0 0266.86TRUE00
2025-01-1750CALL0 0177.12TRUE00
2025-01-177.50CALL0 0128.89TRUE00
2025-01-17100CALL0 095.77TRUE00
2025-01-1712.50CALL0 070.39TRUE00
2025-01-17150CALL0 060.55TRUE00
2025-01-1717.53.26CALL0 663.28TRUE00
2025-01-17207.5CALL0 259.68TRUE00
2025-01-1722.53.65CALL0 2262.72TRUE00
2025-01-17254CALL0 19256.19TRUE00
2025-01-17302.35CALL0 590FALSE00
2025-01-17351.55CALL0 510FALSE00
2025-01-17400.5CALL0 270FALSE00
2025-01-172.50PUT0 00FALSE00
2025-01-1750PUT0 00FALSE00
2025-01-177.50PUT0 00FALSE00
2025-01-17100PUT0 00FALSE00
2025-01-1712.50PUT0 00FALSE00
2025-01-17150PUT0 00FALSE00
2025-01-1717.52PUT0 10FALSE00
2025-01-17202PUT0 30FALSE00
2025-01-1722.51.4PUT0 20FALSE00
2025-01-17252.5PUT0 455.86FALSE00
2025-01-17300PUT0 049.08TRUE00
2025-01-17350PUT0 091.82TRUE00
2025-01-17400PUT0 0108.74TRUE00
2025-04-17150CALL0 057.92TRUE00
2025-04-1717.50CALL0 056.81TRUE00
2025-04-17200CALL0 051.4TRUE00
2025-04-1722.56.23CALL0 151.54TRUE00
2025-04-17254.1CALL0 052.63TRUE00
2025-04-17300CALL0 00FALSE00
2025-04-17350CALL0 00FALSE00
2025-04-17150.5PUT0 100FALSE00
2025-04-1717.50PUT0 00FALSE00
2025-04-17200PUT0 00FALSE00
2025-04-1722.50PUT0 00FALSE00
2025-04-17250PUT0 053.27FALSE00
2025-04-17300PUT0 051.18TRUE00
2025-04-17350PUT0 052.25TRUE00

Latest KNSA Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST8$8.145
Jun 13, 2022 7:59 PM EST4$8.15
Jun 13, 2022 7:59 PM EST5$8.14
Jun 13, 2022 7:59 PM EST50$8.16
Jun 13, 2022 7:59 PM EST7$8.135

Kiniksa Pharmaceuticals, Ltd (KNSA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000163859920000648/0001638599-20-000648-index.htm
2019-06-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1730430/000000000019009529/0000000000-19-009529-index.htm
2020-05-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1730430/000000000020004811/0000000000-20-004811-index.htm
2020-09-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1730430/000000000020008726/0000000000-20-008726-index.htm
2018-07-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000089710118000644/0000897101-18-000644-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000090266419001108/0000902664-19-001108-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000090266420001186/0000902664-20-001186-index.htm
2018-12-13DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1730430/000091205718000516/0000912057-18-000516-index.htm
2018-06-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000092963818000565/0000929638-18-000565-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000092963819000277/0000929638-19-000277-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000093247119005539/0000932471-19-005539-index.htm
2019-01-28S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1730430/000104746919000263/0001047469-19-000263-index.htm
2019-02-01424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1730430/000104746919000331/0001047469-19-000331-index.htm
2019-04-17DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1730430/000104746919002319/0001047469-19-002319-index.htm
2019-06-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1730430/000104746919003431/0001047469-19-003431-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1730430/000104746920002657/0001047469-20-002657-index.htm
2020-05-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1730430/000104746920003043/0001047469-20-003043-index.htm
2020-05-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1730430/000104746920003101/0001047469-20-003101-index.htm
2020-05-21S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1730430/000104746920003168/0001047469-20-003168-index.htm
2020-07-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1730430/000104746920004170/0001047469-20-004170-index.htm
2020-07-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1730430/000104746920004203/0001047469-20-004203-index.htm
2020-06-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000108514620001669/0001085146-20-001669-index.htm
2020-11-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000108514620002765/0001085146-20-002765-index.htm
2018-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465918036453/0001104659-18-036453-index.htm
2018-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918036483/0001104659-18-036483-index.htm
2018-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918036484/0001104659-18-036484-index.htm
2018-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918036485/0001104659-18-036485-index.htm
2018-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918036486/0001104659-18-036486-index.htm
2018-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918036487/0001104659-18-036487-index.htm
2018-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918036488/0001104659-18-036488-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465918049650/0001104659-18-049650-index.htm
2018-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730430/000110465918049660/0001104659-18-049660-index.htm
2018-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465918056557/0001104659-18-056557-index.htm
2018-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465918057064/0001104659-18-057064-index.htm
2018-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918058107/0001104659-18-058107-index.htm
2018-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918058108/0001104659-18-058108-index.htm
2018-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918058109/0001104659-18-058109-index.htm
2018-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918058110/0001104659-18-058110-index.htm
2018-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465918058111/0001104659-18-058111-index.htm
2018-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465918065276/0001104659-18-065276-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465918067898/0001104659-18-067898-index.htm
2019-01-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919003711/0001104659-19-003711-index.htm
2019-01-28FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919003712/0001104659-19-003712-index.htm
2019-01-31FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919004608/0001104659-19-004608-index.htm
2019-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919005120/0001104659-19-005120-index.htm
2019-03-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919013171/0001104659-19-013171-index.htm
2019-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919013172/0001104659-19-013172-index.htm
2019-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919013173/0001104659-19-013173-index.htm
2019-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919013174/0001104659-19-013174-index.htm
2019-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919013175/0001104659-19-013175-index.htm
2019-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919013176/0001104659-19-013176-index.htm
2019-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465919013177/0001104659-19-013177-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919013260/0001104659-19-013260-index.htm
2019-04-17DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1730430/000110465919021965/0001104659-19-021965-index.htm
2019-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919026215/0001104659-19-026215-index.htm
2019-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919033809/0001104659-19-033809-index.htm
2019-06-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1730430/000110465919034373/0001104659-19-034373-index.htm
2019-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919045305/0001104659-19-045305-index.htm
2019-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919056899/0001104659-19-056899-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919064157/0001104659-19-064157-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465919073046/0001104659-19-073046-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920003238/0001104659-20-003238-index.htm
2020-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920011229/0001104659-20-011229-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000110465920018718/0001104659-20-018718-index.htm
2020-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920025055/0001104659-20-025055-index.htm
2020-04-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1730430/000110465920044166/0001104659-20-044166-index.htm
2020-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920049520/0001104659-20-049520-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920051961/0001104659-20-051961-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1730430/000110465920052493/0001104659-20-052493-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920063240/0001104659-20-063240-index.htm
2020-05-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730430/000110465920063267/0001104659-20-063267-index.htm
2020-06-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1730430/000110465920068840/0001104659-20-068840-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920077701/0001104659-20-077701-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465920080547/0001104659-20-080547-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465920080548/0001104659-20-080548-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465920080549/0001104659-20-080549-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465920080550/0001104659-20-080550-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465920080552/0001104659-20-080552-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000110465920080553/0001104659-20-080553-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920081711/0001104659-20-081711-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920083752/0001104659-20-083752-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920086448/0001104659-20-086448-index.htm
2020-07-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920087353/0001104659-20-087353-index.htm
2020-07-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730430/000110465920087438/0001104659-20-087438-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920088133/0001104659-20-088133-index.htm
2020-09-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1730430/000110465920103055/0001104659-20-103055-index.htm
2020-09-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1730430/000110465920105924/0001104659-20-105924-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920117985/0001104659-20-117985-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1730430/000110465920121581/0001104659-20-121581-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000114036118026543/0001140361-18-026543-index.htm
2018-05-31SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730430/000114420418031986/0001144204-18-031986-index.htm
2019-02-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730430/000114420419005387/0001144204-19-005387-index.htm
2019-06-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730430/000114420419030317/0001144204-19-030317-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000117266119000534/0001172661-19-000534-index.htm
2019-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000117266119001914/0001172661-19-001914-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000117266120000889/0001172661-20-000889-index.htm
2020-04-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000117266120001060/0001172661-20-001060-index.htm
2019-05-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019006866/0001179110-19-006866-index.htm
2019-05-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019006867/0001179110-19-006867-index.htm
2019-05-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019006868/0001179110-19-006868-index.htm
2019-05-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019006869/0001179110-19-006869-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019010486/0001179110-19-010486-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019010487/0001179110-19-010487-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019010488/0001179110-19-010488-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019010489/0001179110-19-010489-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019010490/0001179110-19-010490-index.htm
2019-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019010889/0001179110-19-010889-index.htm
2019-11-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019012049/0001179110-19-012049-index.htm
2019-12-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019012550/0001179110-19-012550-index.htm
2019-12-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019012551/0001179110-19-012551-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911019012840/0001179110-19-012840-index.htm
2020-02-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020001564/0001179110-20-001564-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020001565/0001179110-20-001565-index.htm
2020-02-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020001763/0001179110-20-001763-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020001872/0001179110-20-001872-index.htm
2020-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020002033/0001179110-20-002033-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020002714/0001179110-20-002714-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020003417/0001179110-20-003417-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020003831/0001179110-20-003831-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020003833/0001179110-20-003833-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020003834/0001179110-20-003834-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020003835/0001179110-20-003835-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020003836/0001179110-20-003836-index.htm
2020-04-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020005046/0001179110-20-005046-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020007295/0001179110-20-007295-index.htm
2020-07-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020008542/0001179110-20-008542-index.htm
2020-07-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020008544/0001179110-20-008544-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020009719/0001179110-20-009719-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020009720/0001179110-20-009720-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020009721/0001179110-20-009721-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020009722/0001179110-20-009722-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020009723/0001179110-20-009723-index.htm
2020-10-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000117911020010450/0001179110-20-010450-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000119312520037021/0001193125-20-037021-index.htm
2018-05-31SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000119380518000776/0001193805-18-000776-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000119380518000778/0001193805-18-000778-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000119380519000198/0001193805-19-000198-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730430/000119380520000197/0001193805-20-000197-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730430/000155837018008650/0001558370-18-008650-index.htm
2019-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1730430/000155837019001857/0001558370-19-001857-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730430/000155837019004284/0001558370-19-004284-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730430/000155837019008069/0001558370-19-008069-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730430/000155837019009978/0001558370-19-009978-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1730430/000155837020002081/0001558370-20-002081-index.htm
2020-05-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730430/000155837020005040/0001558370-20-005040-index.htm
2020-08-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730430/000155837020009147/0001558370-20-009147-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730430/000155837020012880/0001558370-20-012880-index.htm
2019-04-04DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000156761919008415/0001567619-19-008415-index.htm
2019-07-11D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000156761919014672/0001567619-19-014672-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000163859918000584/0001638599-18-000584-index.htm
2019-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000163859919000191/0001638599-19-000191-index.htm
2019-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000163859919000562/0001638599-19-000562-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000163859919000600/0001638599-19-000600-index.htm
2020-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000163859920000499/0001638599-20-000499-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000163859920000648/0001638599-20-000648-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1730430/000163859920000681/0001638599-20-000681-index.htm
2019-01-30EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1730430/999999999519000039/9999999995-19-000039-index.htm
2019-06-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1730430/999999999519001318/9999999995-19-001318-index.htm
2020-06-04EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1730430/999999999520001340/9999999995-20-001340-index.htm
2020-09-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1730430/999999999520002521/9999999995-20-002521-index.htm
2018-05-25CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1730430/999999999718005811/9999999997-18-005811-index.htm
2020-02-07SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1730430/999999999720000601/9999999997-20-000601-index.htm
2020-02-19SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1730430/999999999720000808/9999999997-20-000808-index.htm

Kiniksa Pharmaceuticals, Ltd (KNSA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kiniksa Pharmaceuticals, Ltd (KNSA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 618%
Institutional Ownership: 8731%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-10-09Sanj K PatelChairman & CEOSell872.0021.0018,312.000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020010450/0001179110-20-010450-index.htm
2020-10-12Sanj K PatelChairman & CEOSell150,700.0021.023,167,714.000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020010450/0001179110-20-010450-index.htm
2020-07-01Thomas W. BeethamEVP & Chief Legal OfficerSell2,855.0025.8473,773.200.00https://www.sec.gov/Archives/edgar/data/1730430/000110465920080552/0001104659-20-080552-index.htm
2019-10-07John F. PaoliniSVP & Chief Medical OfficerBuy10,000.001.8618,600.0010,000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911019010889/0001179110-19-010889-index.htm
2020-10-12Sanj K PatelChairman & CEOSell99,330.0021.022,087,916.60112,570.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020010450/0001179110-20-010450-index.htm
2020-10-12Sanj K PatelChairman & CEOBuy150,700.001.59239,613.00150,700.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020010450/0001179110-20-010450-index.htm
2020-02-13John F. PaoliniSVP & Chief Medical OfficerSell10,277.0018.29187,966.3318,000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020001763/0001179110-20-001763-index.htm
2020-02-14John F. PaoliniSVP & Chief Medical OfficerSell1,039.0018.3319,044.8718,000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020001763/0001179110-20-001763-index.htm
2020-02-19John F. PaoliniSVP & Chief Medical OfficerSell22,477.0018.27410,654.7918,000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020002033/0001179110-20-002033-index.htm
2020-02-20John F. PaoliniSVP & Chief Medical OfficerSell1,116.0019.3221,561.1218,000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020002033/0001179110-20-002033-index.htm
2020-02-14John F. PaoliniSVP & Chief Medical OfficerBuy1,039.003.803,948.2019,039.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020001763/0001179110-20-001763-index.htm
2020-02-20John F. PaoliniSVP & Chief Medical OfficerSell8,687.0018.91164,271.1719,116.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020002033/0001179110-20-002033-index.htm
2020-10-09Sanj K PatelChairman & CEOSell670.0021.0014,070.00211,900.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020010450/0001179110-20-010450-index.htm
2020-03-06Sanj K PatelChairman & CEOSell33,115.0020.00662,300.00212,570.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020003417/0001179110-20-003417-index.htm
2018-05-29BROS. ADVISORS LP BAKERDirectorBuy2,700,597.0018.0048,610,746.002,700,597.00https://www.sec.gov/Archives/edgar/data/1730430/000163859918000584/0001638599-18-000584-index.htm
2020-02-20John F. PaoliniSVP & Chief Medical OfficerBuy9,803.003.8037,251.4027,803.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020002033/0001179110-20-002033-index.htm
2020-02-13John F. PaoliniSVP & Chief Medical OfficerBuy10,277.003.8039,052.6028,277.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020001763/0001179110-20-001763-index.htm
2020-07-01Thomas W. BeethamEVP & Chief Legal OfficerSell26,734.0025.32676,904.882,855.00https://www.sec.gov/Archives/edgar/data/1730430/000110465920080552/0001104659-20-080552-index.htm
2020-04-21Thomas W. BeethamEVP & Chief Legal OfficerSell955.0020.4419,520.2029,589.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020005046/0001179110-20-005046-index.htm
2020-06-10Thomas W. BeethamEVP & Chief Legal OfficerSell13,752.0025.07344,762.6429,589.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020007295/0001179110-20-007295-index.htm
2018-05-29BROS. ADVISORS LP BAKERDirectorBuy299,403.0018.005,389,254.00299,403.00https://www.sec.gov/Archives/edgar/data/1730430/000163859918000584/0001638599-18-000584-index.htm
2020-02-27John F. PaoliniSVP & Chief Medical OfficerBuy12,000.001.8622,320.0030,000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020002714/0001179110-20-002714-index.htm
2020-04-21Thomas W. BeethamEVP & Chief Legal OfficerSell1,563.0019.5630,572.2830,544.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020005046/0001179110-20-005046-index.htm
2020-04-20Thomas W. BeethamEVP & Chief Legal OfficerSell47,423.0019.06903,882.3832,107.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020005046/0001179110-20-005046-index.htm
2018-05-29James E Flynn10% Share HolderBuy333,333.0018.005,999,994.00333,333.00https://www.sec.gov/Archives/edgar/data/1730430/000119380518000778/0001193805-18-000778-index.htm
2020-02-19John F. PaoliniSVP & Chief Medical OfficerBuy22,477.003.8085,412.6040,477.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020002033/0001179110-20-002033-index.htm
2020-06-10Thomas W. BeethamEVP & Chief Legal OfficerBuy13,752.001.5921,865.6843,341.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020007295/0001179110-20-007295-index.htm
2018-05-29James E Flynn10% Share HolderBuy250,000.0019.814,953,150.00583,333.00https://www.sec.gov/Archives/edgar/data/1730430/000119380518000778/0001193805-18-000778-index.htm
2018-05-29James E Flynn10% Share HolderBuy25,000.0020.91522,747.50608,333.00https://www.sec.gov/Archives/edgar/data/1730430/000119380518000778/0001193805-18-000778-index.htm
2020-02-14Thomas W. BeethamEVP & Chief Legal OfficerSell59.0018.581,096.2279,530.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020001872/0001179110-20-001872-index.htm
2019-12-05John F. PaoliniSVP & Chief Medical OfficerBuy8,000.001.8614,880.008,000.00https://www.sec.gov/Archives/edgar/data/1730430/000117911019012550/0001179110-19-012550-index.htm
2018-05-29James E Flynn10% Share HolderBuy235,019.0019.244,520,942.99843,352.00https://www.sec.gov/Archives/edgar/data/1730430/000119380518000778/0001193805-18-000778-index.htm
2020-10-09Sanj K PatelChairman & CEOBuy872.001.591,386.48872.00https://www.sec.gov/Archives/edgar/data/1730430/000117911020010450/0001179110-20-010450-index.htm
2018-05-29Cormorant Asset Management, LP10% Share HolderBuy69,444.0018.001,249,992.00900,443.00https://www.sec.gov/Archives/edgar/data/1730430/000114036118026543/0001140361-18-026543-index.htm